Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
15 May 2018 - 9:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced that it will
present results from eight studies at the 2018 American Society of
Clinical Oncology (ASCO) annual meeting to be held June 1 to 5,
2018 in Chicago, Ill. Abstracts of the Company's
presentations will be available at: abstracts.asco.org on May 16 at
5:00 p.m. EDT.
“We look forward to presenting exciting new discoveries at ASCO
that we believe will expand the reach of personalized medicine for
patients with cancer,” said Johnathan Lancaster, M.D., Ph.D., chief
medical officer, Myriad Genetics. “Importantly, our
presentations will focus on new advances in predicting breast
cancer recurrence and the need for chemotherapy, the role of
hereditary cancer testing in preventing cancer or optimizing
treatment plans, and novel companion diagnostics for helping guide
medication selection for patients with breast or ovarian
cancers.”
A list of Myriad presentations at ASCO 2018 are below.
Follow Myriad on Twitter via @MyriadGenetics and stay
informed about symposium news and updates by using the hashtag
#ASCO18.
Title |
Presenter |
Abstract Number |
Day/Time |
Myriad Product |
|
|
|
|
|
Oral Presentation |
|
|
|
|
|
|
|
|
|
Validation
of a Combined Residual Risk Score for Healthy Unaffected Women
Presenting to Breast Cancer (BC) Screening Centers |
Kathryn
Dalton |
Presentation 1507 |
Sunday,
June 3, 2018: 8:00-11:30 a.m. CDT. |
riskScore |
|
|
|
|
|
Poster Presentations |
|
|
|
|
|
|
|
|
|
Predicting
Expected Absolute Chemotherapy Treatment Benefit in Women with
Early-Stage Breast Cancer using a 12-Gene Expression Assay |
William
Gradishar |
Abstract
525 |
Saturday,
June 2, 2018: 8:00-11:30 a.m. |
EndoPredict |
|
|
|
|
|
In Silico
Evaluation of the 12-gene molecular score (EndoPredict) and the
Recurrence Score (Oncotype DX) as Predictors of Response to
Neo-adjuvant Chemotherapy in Estrogen Receptor Positive (ER+), HER2
Negative (HER2-) Breast Cancer |
Hatem
Soliman |
Abstract
539 |
Saturday,
June 2, 2018: 8:00-11:30 a.m. CDT. |
EndoPredict |
|
|
|
|
|
Promoting
Colorectal Cancer (CRC) Screening after Multiplex Genetic Testing
and Genetic Counselling |
Gregory
Idos |
Abstract
1582 |
Saturday,
June 2, 2018: 1:15-4:45 p.m. CDT. |
Myriad
myRisk |
|
|
|
|
|
Promoting
Breast Cancer Screening after Multiplex Genetic Panel Testing
(MGPT) and Genetic Counselling |
Gregory
Idos |
Abstract
1581 |
Saturday,
June 2, 2018: 1:15-4:45 p.m. CDT. |
Myriad
myRisk |
|
|
|
|
|
Evaluation
of Homologous Recombination Deficiency (HRD) status with
pathological response to carboplatin +/- veliparib in BrighTNess, a
randomized phase 3 study in early stage TNBC |
Melinda
Telli |
Abstract
519 |
Saturday,
June 2, 2018: 3:00-4:15 p.m. CDT. |
myChoice
HRD |
|
|
|
|
|
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated
(mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19
(NCT00753545) clinical trials |
Kirsten
Timms |
Abstract
5563 |
Monday,
June 4, 2018: 1:15-4:45 p.m. CDT. |
myChoice
HRD |
About EndoPredict®EndoPredict is a
second-generation, multigene prognostic test for patients diagnosed
with ER+, HER2- early-stage breast cancer. The test provides
physicians with information to devise personalized treatment plans
for their patients. EndoPredict has been validated in
approximately 4,000 patients with node-negative and node-positive
cancer and has been used clinically in more than 20,000
patients. In contrast to first-generation multigene
prognostic tests, EndoPredict detects the likelihood of late
metastases (i.e., metastasis formation after more than five years)
and, therefore, can guide treatment decisions regarding the need
for chemotherapy, as well as extended anti-hormonal therapy.
Accordingly, therapy decisions backed by EndoPredict confer a high
level of diagnostic safety. For more information, please visit:
www.endopredict.com.
About Myriad myRisk® Hereditary CancerThe
Myriad myRisk Hereditary Cancer panel uses validated technologies
and algorithms in an 850 step laboratory process to evaluate 28
clinically significant genes associated with eight hereditary
cancer sites including: breast, colon, ovarian, endometrial,
pancreatic, prostate and gastric cancers and melanoma. For
more information, please visit:
https://www.myriad.com/products-services/hereditary-cancers/myrisk-hereditary-cancer/.
About riskScoreTMriskScore is a clinically
validated algorithm that predicts a women's remaining 5-year and
lifetime risk of developing breast cancer. The algorithm combines
the analysis of over 80 well-studied genetic markers and the
Tyrer-Cuzick model to accurately estimate breast cancer risk for
woman of European descent. For more information, please visit:
https://new.myriadpro.com/riskscore/
About myChoice® HRDMyriad's myChoice HRD is the
first homologous recombination deficiency test that can detect when
a tumor has lost the ability to repair double-stranded DNA breaks,
resulting in increased susceptibility to DNA-damaging drugs such as
platinum drugs or PARP inhibitors. High myChoice HRD scores
reflective of DNA repair deficiencies are prevalent in all breast
cancer subtypes, ovarian and most other major cancers. In
previously published data, Myriad showed that the myChoice HRD test
predicted drug response to platinum therapy in certain patients
with triple-negative breast and ovarian cancers. It is
estimated that 1.8 million people in the United States and Europe
who are diagnosed with cancers annually may be candidates for
treatment with DNA-damaging agents. For more information, please
visit: https://myriadmychoice.com/
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com. Myriad, the Myriad logo, BART,
BRACAnalysis, COLARIS, COLARIS AP, myPath, myRisk, Myriad myRisk,
myRisk Hereditary Cancer, myChoice, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight,
riskScore and Prolaris are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor
Statement This
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to data being presented at the at the
2018 American Society of Clinical Oncology Annual Meeting being
held June 1-5, 2018 in Chicago, Ill.; the Company’s belief that new
discoveries being presented at ASCO will expand the reach of
personalized medicine for patients with cancer; the focus of these
presentations on new advances in predicting breast cancer
recurrence and the need for chemotherapy, the role of hereditary
cancer testing in preventing cancer or optimizing treatment plans,
and novel companion diagnostics for helping guide medication
selection for patients with breast or ovarian cancers; and the
Company's strategic directives under the caption "About Myriad
Genetics." These "forward-looking statements" are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those described or
implied in the forward-looking statements. These risks include, but
are not limited to: the risk that sales and profit margins of our
existing molecular diagnostic tests and pharmaceutical and clinical
services may decline or will not continue to increase at historical
rates; risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers' reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of Assurex,
Sividon and the Clinic; risks related to our projections about the
potential market opportunity for our products; the risk that we or
our licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of
our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our Annual report on Form 10-K for the fiscal year ended
June 30, 2017, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
Media Contact:
|
Ron Rogers |
|
Investor Contact:
|
Scott Gleason |
|
(801) 584-3065 |
|
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024